Veratridine: Precision Voltage-Gated Sodium Channel Opener for Advanced Research

Executive Summary: Veratridine (CAS: 71-62-5) is a potent steroidal alkaloid neurotoxin extracted from Veratrum species, used extensively in neuroscience and oncology research. It acts as an irreversible voltage-gated sodium channel opener by binding to site 2, preventing channel inactivation and inducing persistent depolarization (APExBIO; Saito et al., 2025). This mechanism is foundational for experiments studying sodium channel dynamics, excitotoxicity, and mechanisms underlying seizure and cancer cell death. Veratridine is soluble in DMSO >33.69 mg/mL, has a molecular weight of 673.79 g/mol, and is recommended to be stored at -20°C. It has been validated to enhance UBXN2A protein levels and promote mortalin-2 dependent cancer cell death in vitro and in vivo, making it a valuable tool for translational and screening studies. Its use is for research purposes only, not for clinical or diagnostic application.

Biological Rationale

Voltage-gated sodium channels (Nav) are essential for electrical signaling in excitable cells such as neurons, cardiomyocytes, and muscle fibers. Persistent activation or dysregulation of these channels contributes to pathological states, including epilepsy, neuropathic pain, arrhythmias, and certain cancers (Saito et al., 2025). Steroidal alkaloid neurotoxins like Veratridine provide a controlled means to probe sodium channel function and model disease processes linked to abnormal channel activity. By preventing channel inactivation and maintaining depolarization, Veratridine allows researchers to dissect downstream effects, including excitotoxicity and apoptotic signaling, and to test the efficacy of sodium channel blockers in screening assays. In cancer models, sodium channel modulation is implicated in cell survival and chemosensitivity (Veratridine (SKU B7219): Data-Driven Solutions).

Mechanism of Action of Veratridine

Veratridine binds specifically to site 2 of voltage-gated sodium channels, distinct from the local anesthetic and tetrodotoxin binding sites. This binding prevents the rapid inactivation of the channel, resulting in a persistent sodium current. The ensuing sustained depolarization leads to increased intracellular sodium, altered calcium signaling, and potential excitotoxic cell death. In experimental systems, this property is leveraged to induce controlled channel opening, facilitate functional assays, and mimic disease-relevant states. The molecular formula is C36H51NO11, and it appears as a white solid. For optimal integrity, it should be stored at -20°C and solutions should be used promptly (APExBIO).

Evidence & Benchmarks

• Veratridine induces persistent depolarization in neurons and cardiomyocytes by binding to site 2 on Nav channels (Saito et al., 2025).
• In cell-based assays, Veratridine increases UBXN2A protein expression in a dose-dependent manner, enhancing cancer cell death via mortalin-2 dependent pathways (APExBIO).
• In vivo, intraperitoneal injection of Veratridine at 0.125 mg/kg for 28 days led to significant UBXN2A induction and colon cancer cell death (APExBIO).
• Veratridine is widely used in screening assays for sodium channel blockers, enabling reproducible benchmarking of compound potency (Data-Driven Solutions).
• In cardiomyocyte differentiation studies, Veratridine is used to validate functional Nav channel expression and probe chamber-specific electrophysiology (Saito et al., 2025).

Applications, Limits & Misconceptions

Veratridine is a reference tool in sodium channel dynamics research, excitotoxicity studies, seizure mechanism research, and oncology workflows. It is crucial for:

• Probing persistent Nav channel activation in electrophysiological assays.
• Validating cardiomyocyte differentiation and chamber-specific function in human pluripotent stem cell models (Veratridine: Next-Gen Insights; this article extends prior work by detailing quantitative benchmarks and workflow integration parameters).
• Enhancing UBXN2A-mediated cancer cell death and modulating chemosensitivity (Precision Voltage-Gated Sodium Channel Opener; here, we provide updated evidence on dose-response in animal models).
• Development and benchmarking of sodium channel blocker screening assays.

Common Pitfalls or Misconceptions

• Veratridine does not selectively target individual Nav channel subtypes; it broadly affects all site 2-positive isoforms.
• It is not suitable as a therapeutic agent due to its potent neurotoxic effects and lack of reversibility.
• Long-term storage of Veratridine solutions is discouraged; activity may decline even at -20°C.
• Cellular responses to Veratridine can vary significantly by cell type and experimental conditions, necessitating careful controls.
• It is not intended for diagnostic or clinical use and should be handled under research-use-only protocols (APExBIO).

Workflow Integration & Parameters

APExBIO’s Veratridine (SKU B7219) is provided as a white solid (MW: 673.79) and is soluble in DMSO at >33.69 mg/ml (>10 mM). For use, it is reconstituted in DMSO and diluted into physiological buffers immediately before experiments. Optimal stability requires -20°C storage and avoidance of repeated freeze-thaw cycles. In cell experiments, Veratridine is applied in a range of 1–30 μM, with cytotoxic effects and protein induction monitored over 4–48 h. In animal studies, dosing at 0.125 mg/kg i.p. for 28 days has been reported to induce UBXN2A expression. It is compatible with electrophysiological, viability, and protein quantification assays. For sodium channel blocker screening, Veratridine-induced persistent current serves as a robust baseline for inhibitor titration (Veratridine at the Translational Frontier; this article details workflow-specific solubility and storage guidelines not previously described).

Conclusion & Outlook

Veratridine remains a cornerstone tool for the study of voltage-gated sodium channel physiology and pathophysiology. Its validated performance in sodium channel dynamics, excitotoxicity, seizure mechanism research, and cancer chemosensitivity modeling is supported by rigorous benchmarks and well-defined protocols. APExBIO’s Veratridine (B7219) delivers high reproducibility and purity for advanced research applications. Future studies may expand its role in precision modeling of chamber-specific cardiomyocytes and mechanistic oncology research. For detailed product specifications and ordering, visit the Veratridine product page.